← Eichor
Study identifier: NCT05349006 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Azathioprine in MOGAD

Condition: Central Nervous System Inflammation · MOG-IgG Associated Disease  ·  Sponsor: Hospices Civils de Lyon

PhasePhase 3
Planned participants126
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from incident cohorts suggests that around 50% of adult patients with MOG-Ab may relapse within the first two years of the disease, with most of relapses occurring early after disease onset. No randomized controlled trial has ever been performed and therapeutic guidelines for this disease remain unclear especially after a single event. In short-sized and mainly retrospective study, azathioprine, an immunosuppressant drug, have showed promising results on preventing the risk of relapse in MOGAD patients. The hypothesis is that the initiation of a treatment after a first attack of MOGAD should prevent further relapse and disability accrual. The investigators propose herein the first randomized controlled trial in MOGAD, to evaluate the efficacy of azathioprine to prevent relapses, after a first attack, in a placebo double-blinded design.

This description comes directly from the study's public registry record.

Talk to the study team

Romain MARIGNIER, MD PhD  ·  +334 72 35 75 22  ·  romain.marignier@chu-lyon.fr

Lakhdar BENYAHYA, project manager  ·  +334 72 68 49 07  ·  lakhdar.benyahya@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (17)

Department of Neurology, CHU de Bordeaux - GH PellegrinBordeaux, FranceRecruiting
Department of Neurology, CHU of Lille, Hospital Roger SalengroLille, FranceRecruiting
Department of Neuro Ophthalmology, CHU of Lyon, Neurology Hospital Pierre WertheimerLyon, FranceRecruiting
Service de Neurologie sclérose en plaques, pathologies de la myéline et neuro-inflammation - Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) - Hôpital Neurologique Pierre Wertheimer - Hospices Civils de LyonLyon, FranceRecruiting
Department of Neurology University hospital TimoneMarseille, FranceRecruiting
Department of Neurology Montpellier Universitary HospitalMontpellier, FranceRecruiting
CHRU de Nancy Hôpital CentralNancy, FranceRecruiting
Department of Neurology, Hôpital Pasteur 2Nice, FranceNot Yet Recruiting
Department of Neurology, Hôpital CaremeauNîmes, FranceRecruiting
National Hospital of Vision (15-20)Paris, FranceRecruiting
Department of Neurology APHP, Pitié Salpêtrière HospitalParis, FranceRecruiting
Department of Neurology. Hôpital A. Fondation RothschildParis, FranceRecruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05349006